Abstract
Despite important drug development for HNSCC’s patients (pts) prognostic is still pejorative. HNSCC’s pts don’t routinely benefit of molecular screening (MS) and currently no molecular characteristic lead to driven treatment in their standard of care.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
